News
Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys
Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy treatment Elevidys. Shares were trading around $20.61. The stock is down 70% on the year.
Liver damage is a well-recognised complication of gene therapies based on adeno-associated virus (AAV) vectors, and other ...
A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...
Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...
Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...
Sarepta Therapeutics (NASDAQ:SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback